



OTC: XCRT

One Step Ahead



The Healthcare Challenge.


- Healthcare is not failing due to lack of innovation—it is failing to translate existing innovation from engineering into clinical care.
- Healthcare innovation is constrained not by lack of technology, but by a structural disconnect between advanced non-medical engineering and clinical application. As a result, proven breakthroughs in other industries remain underutilized in medicine, slowing the adoption of transformative care solutions.

Innovation Takes 17 Years to Become Routine Care

Innovation takes 17 years to become routine care, reflecting a systemic delay in translating evidence-based practices into clinical adoption ([Rita Rubin, 2023](#)).




Our Smart **Solution**




Translational Intelligence Platform

Builds an internationally recognized network of clinicians and engineers to identify underutilized engineering breakthroughs and intellectual property with latent medical applications.



Acquisition-Led Innovation Strategy

Sources and acquires technology at the engineering and patent level, focusing on proven or emerging innovations outside traditional healthcare R&D pipelines.



Cross-Sector MedTech Integration

Bridges non-medical engineering advancements with early-stage medtech companies to rapidly adapt and align technologies for clinical use.



Our Smart **Solution**



Clinical Development Ecosystem

Combines engineering, clinical care, and business operations within a single controlled environment, enabling real-world testing, iteration, and validation.



Low Cost Commercialization Model

Sources and acquires technology at the engineering and patent level, focusing on proven or emerging innovations outside traditional healthcare R&D pipelines.





About Xcelerate Inc.

One Step Ahead



Xcelerate seeks to acquire rather than develop its technology / healthcare delivery. We understand that engineering advancements in non-medical fields often have unrealized applications in medical technology & clinical care and the silos existing between advanced engineering and medicine have been poorly bridged. Xcelerate is unique in that it was designed from inception to span the divide between initial non-medical engineering advancements and its application to clinical care.




Our Vision & Mission

One Step Ahead



Our Vision

A world where breakthrough medical innovations reach every patient quickly, affordably, and equitably.



Our Mission

To bridge engineering and clinical care by accelerating medtech innovation from concept to real-world use, reducing development barriers, lowering costs, and expanding access to underserved communities.

Market Opportunity



Xcelerate targets the inefficiency gap within a \$600B+ medtech market embedded in a \$9T+ global healthcare system.

01

\$600B+ Global MedTech Market

The global medical technology market is valued at over \$600 billion and growing ~5–6% annually, driven by demand for diagnostics, devices, and digital health solutions.

02

\$2T+ Global Healthcare Spending Efficiency Gap

Global healthcare spending exceeds \$9 trillion annually, with estimates suggesting 20–30% is wasted on inefficiency and delayed adoption of better technologies

03

\$30B–\$70B Annual MedTech M&A Activity

The medtech sector consistently sees tens of billions in annual acquisitions, reflecting strong demand for innovative technologies and scalable intellectual property

Target Audience



Engineering & IP Owners

Non-medical engineering firms, research institutions, universities, and patent holders with technologies that have unrealized healthcare applications.



Early-Stage MedTech Companies

Seed to growth-stage companies needing engineering expertise, clinical validation environments, and accelerated commercialization pathways.



Healthcare & Commercialization Partners

Clinical care facilities, healthcare operators, strategic acquirers, and investors supporting validation, deployment, and market adoption.



Our Growth Journey

01

2020-2021

Vision, Foundation & IP Acquisition

- New business plan launched (May 2020).
- Defined the core model:
 - Medical IP / patents / technology licensing
 - Virtual healthcare solutions for emerging markets
- Finalized the initial Membership Interest Purchase Agreement to acquire a 51% controlling interest in AfiyaSasa Africa, LLC.

02

2022-2023

Dual-Revenue Scaling

- Expanded into consumer healthcare by acquiring 51% of ESN Group (Earth Science and Ceramedx).
- Built baseline corporate revenues from established retail skincare distributions.
- Funded foundational infrastructure and software protocols for African clinical deployments.

03

2024-2025

Strategic Divestment & Pivot

- Conducted comprehensive capital review to unlock pure-play tech valuation.
- Sold majority interest in ESN Group for an all-cash payout.
- Cleared related merchant debt, redirecting 100% of capital to telehealth.
- Strategic refocus to

04

2026+

AI Medtech Scale & Deployment

- Transitioned the AfiyaSasa platform from a strategic blueprint into live, localized operational testing.
- Contracted Tanzanian medical doctor Dr. Desire Ruhinda to align AI healthcare software with regional treatment guidelines.

WHY Xcelerate Acquired Afya SASA

Expanding Xcelerate Beyond MedTech IP Into Scalable AI Healthcare Delivery

The Challenge

Traditional MedTech commercialization can face:

-  Long commercialization timelines
-  Capital intensive market entry
-  Limited direct patient engagement
-  Dependence on hospital adoption cycles

Why AFYA SASA Matters

Afya Sasa creates a healthcare delivery platform

-  AI-enabled digital healthcare infrastructure
-  Emerging market healthcare access model
-  Regional healthcare partnerships & networks
-  Virtual care + referral ecosystem
-  Direct patient access channel




How This Benefits Xcelerate



Diversifies Revenue Potential

Moves beyond pure IP ownership into: SaaS, Digital health, Membership models, Healthcare transaction revenues.



Creates Commercialization Pathways

Potential future deployment environment for: AI healthcare technologies, Diagnostics, Medical innovations, Clinical workflow solutions




Expands Global market opportunity

Access to high-growth, underserved healthcare markets (Asia & Africa)


Afya Sasa strengthens Xcelerate's transition from technology ownership towards scalable healthcare platform execution


Strategic Synergies & Long Term Value Creation


How Afya Sasa enhances the Xcelerate ecosystem



 Strengthen Xcelerate's position in AI-driven healthcare innovation

 Creates a platform for sustainable global growth

 Diversifies revenue streams and accelerates value creation

 Built for scale, impact and long-term returns



Meet **The CEO**

Michael O'Shea

Chief Executive Officer

Mike O'Shea is a forensic accountant and licensed financial investigator. He has worked closely with such agencies as the Federal Deposit Insurance Corporation, Resolution Trust Corporation, FBI, Office of the Controller of the Currency, US Secret Service and ATF. He has been admitted, on numerous occasions, as an expert witness in forensic accounting in both Federal and State court as well as foreign jurisdictions. During his 25+ year career he has served as a court appointed receiver and financial crimes investigator on numerous occasions.

Since 1999, Mike has been the Director of Forensic Research Group, Inc. and has been responsible for implementing and supervising its forensic accounting, financial investigation, and corporate due diligence programs. From 1985-1998 Mike served as Director of Investigations for Investigative Research Group, Inc., a firm that specialized in corporate due diligence, asset searches, bankruptcy review, and loan recovery. The Company had Bank of New York, Chemical Bank, Summit Bancorp, and the New Jersey Economic Authority among its long list of noteworthy clients.



Meet **The Directors**

Jason Householder

Director

Jason Householder, Co-Founder and CEO of Charlotte based LenDRgroup Consulting, has more than a decade of experience in the healthcare banking field and specializes in assisting medical, dental, and veterinary practices to devise strategies that run their businesses effectively and achieve peak performance. LenDRgroup has financed over \$300mil in practice loans to dentists, physicians, and veterinarians.

Jon Wilken

Director

Jon Wilken, President and CEO of HS Pharmaceuticals, is a 30-year veteran of the retail food industry. He is the former President and CEO of BILO Inc., a supermarket chain which at the time of his employment was wholly owned by Ahold NV of The Netherlands. While Jon was at BILO, the company employed approximately 26,000 associates and operated over 400 retail supermarkets and convenience stores in four Southeastern States with annual sales of approximately \$4.0 Billion. Since leaving Ahold/BILO in 2002 Jon has pursued entrepreneurial business ventures including partnering in a 250+ acre commercial and retail real estate planned development, The Point, in Greenville, South Carolina. The project to date has a Whole Foods supermarket, a retail shopping center, several restaurants, over 500 apartments, 8 hotels, and a 40-acre TD Bank call center campus.



Meet **The Research Team**

Dr. Ania Glisovic

Chief Science Officer

Dr. Glisovic received her PhD in X-Ray and Material Physics from Germany's Georg-August Universitat in 2007. She went on to become the head of the R&D Laboratory, Chief Science Officer, and R&D Project Leader for the Fraunhofer Institute, the world's leading applied research organization.

Dr. Glisovic will be bringing her vast experience in scientific research and development, as well as project leadership at the highest levels, to the Xcelerate Team. She holds numerous patents in the fields of medical devices, chemical engineering, and small arms and munitions. Her primary initial responsibility with the Xcelerate will be identifying and developing business combinations and high growth opportunities in the medical arena.



Meet The Advisory Board

Dr. Barry Marshall

AC. FRACP, FAA, FRS, MBBS-UWA

Professor Barry Marshall is a Nobel Prize Laureate, Professor of Clinical Microbiology at The University of Western Australia. Professor Marshall was awarded the 2005 Nobel Prize for Physiology or Medicine for their discovery of the bacterium *Helicobacter pylori* (*H.pylori*) and its role in gastritis and peptic ulcer disease. This discovery has benefited millions of people, maybe saving a million lives over the last 10-20 years. Today, Professor Marshall is the Director of The Marshall Centre for Infectious Diseases Research and Training, which was founded in his honor. In addition to *H. pylori* research, the Marshall Centre is at the forefront of infectious disease identification and surveillance, diagnostics and drug design, and transformative discovery. Professor Marshall has several projects including studying the relationship *H.pylori* has with the immune system. Professor Marshall and his team are developing a medication that uses the bacteria to rebalance an overactive immune system and prevent asthma and food allergies. The *Helicobacter pylori* Research Group is taking up the challenge to develop new diagnostics and treatments to target *H. pylori* across the globe. The research team is focused on the prevention, diagnosis and treatment of *H. pylori* using clinical microbiology, molecular biology, immunology, genomics and systems biology.

Dr. Dilan B. Ellegala

MD, FAANS

Dr. Ellegala has been at the forefront of clinical care and medical technology development for two decades. An honors graduate of the University of Washington School of Medicine, he served academic leadership roles as Director of Neurotrauma and Cerebrovascular Neurosurgery at major universities, co-founding Deon for Global Health, and has had collaborations with the Wellman Center for Photomedicine at MIT/Harvard, Clemson Bioengineering, and private industry. He has authored over 50 peer-reviewed research publications and holds multiple patents in ultrasound technology. Dr. Ellegala has successfully commercialized medical technology and applied it to advance clinical care. He has founded several successful medical companies including Sonospine LLC, a pioneer in ultrasonic spine surgery, and a virtual health company recently acquired by AdviNOW, LLC which applies artificial intelligence to healthcare. His groundbreaking work in global medical education is documented in the book, "A Surgeon in the Village: An American Doctor Teaches Brain Surgery in Africa", which was written by Pulitzer-nominated journalist Tony Bartleme. NBC's Tom Brokaw described the work as "A lyrical, inspirational and altogether rewarding account of first- and third-world surgeons working together to perform neurosurgery miracles in the heart of Africa."



Corporate **Information**

Corporate Structure




- Symbol: XCRT
- Cusip: 98401T105
- U.S. Reporting: SEC Reporting – Reg A
- Shell: No
- Shares Authorized: 1,000,000,000
- Shares outstanding: 434,446,072
- Restricted: 287,319,635
- Unrestricted: 147,126,437
- Public Float: 113,254,438

Information as of 6/30/2026





Come Join Us!

-  854-900-2020
-  info@xcelerate.global
-  www.Xcelerate.global

